Raymond Y. Huang, MD, Ph.D., of the Division of Radiology at Brigham and Girls’s Hospital, is the corresponding creator of a paper revealed within the Journal of Medical Oncology, “Comparative Evaluation of Intracranial Response Evaluation Standards in Sufferers With Melanoma Mind Metastases Handled With Mixture Nivolumab + Ipilimumab in CheckMate 204.”
How would you summarize your examine for a lay viewers?
Our examine examines how completely different imaging standards can be utilized to evaluate mind tumor responses in sufferers with melanoma handled with immunotherapy medication. We recognized one imaging technique that was extra correct in predicting survival in comparison with others. Whereas additional work is required, our examine is promising and highlights the significance of extra constant imaging requirements in scientific trials.
What strategies or method did you employ?
We checked out completely different measurements of mind metastases (tumors that kind when most cancers cells unfold to the mind) on MRI scans taken over the course of two years or longer for sufferers in a multi-center section 2 scientific trial evaluating an immunotherapy for mind most cancers. We took into consideration the affected person’s response to the remedy, together with progression-free survival (PFS) and total survival (OS), to find out which set of standards was most predictive of affected person end result.
What did you discover?
We discovered {that a} modified imaging method (mRECIST) and volumetric measurements (3D measurement evaluation) have been extra correct in predicting survival in comparison with different strategies. These approaches labored properly even for small tumors, suggesting they need to be included in future research when evaluating remedy response.
What are the implications?
General, these findings goal to enhance how oncologists consider and deal with mind metastases in most cancers sufferers.
What are the subsequent steps?
We’re at the moment creating computerized segmentation know-how to enhance the consistency of 3D tumor measurements, with the aim of constructing a typical instrument for evaluating mind metastases.
Supply:
Journal reference:
Huang, R. Y., et al. (2025). Comparative Evaluation of Intracranial Response Evaluation Standards in Sufferers With Melanoma Mind Metastases Handled With Mixture Nivolumab + Ipilimumab in CheckMate 204. Journal of Medical Oncology. doi.org/10.1200/jco.24.00953.